We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

2 FTSE 250 stocks I’d buy for 2020

G A Chester highlights two FTSE 250 (INDEXFTSE:MCX) stocks where he sees catalysts for high investment returns.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Shares of healthcare firm ConvaTec (LSE: CTEC) and travel operator FirstGroup (LSE: FGP) have performed strongly this year. Looking ahead, I believe both these FTSE 250 stocks can continue to deliver. Here are the reasons why I’d buy them today for 2020.

Fundamentally attractive

ConvaTec is a stock I originally tipped far too soon after it debuted on the stock market in 2016. I’m generally cautious on new arrivals until they’ve built up a record as a publicly-listed company, but I was swayed by CTEC’s market-leading products and technologies for the management of chronic conditions.

Should you buy Convatec Group Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

The company soon reported a number of operational issues, and the share price suffered as a result. However, I continue to see the business as fundamentally attractive, with ageing populations being a structural driver for growth. The shares have climbed around 50% since I kept faith with the company earlier this year. Events since, including a Q3 trading update today, have persuaded me there’s more to come.

On track

With a new chairman and chief executive, ConvaTec reported a Q3 performance in line with management expectations, and said its transformation initiative is on track. Advanced wound care produced organic revenue growth of 3.6% for the period, and with ostomy care (+3%), continence and critical care (+8%), and infusion devices (+4.3%), there was growth across all franchises.

Management left its guidance for the full-year unchanged. Namely, group organic revenue growth of 1% to 2.5%, and an adjusted EBIT margin of 18% to 20%, including spend associated with the transformation initiative and costs to implement new medical device regulations.

Plans and progress

Highly-rated chief executive Karim Bitar, who joined the company just a month ago, said: “I look forward to giving an update on our plans and progress next year.” I’d expect this to be alongside full-year results in February.

At a share price of around 200p, CTEC trades at 20 times current-year forecast earnings. I’m hopeful Bitar’s plans for growth, an ongoing reduction of debt, and an improving business performance could see the share price continue to head north through 2020.

Portfolio rationalisation

FirstGroup announced its annual results back in May, along with a strategy update for its portfolio of five market-leading public transportation businesses in the UK and North America. It intends to make the latter its core market, centred on its contract-based operations First Student and First Transit. It said a formal sale process is underway for its iconic Greyhound intercity coaches business.

In the UK, it’s pursuing structural alternatives to separate its First Bus operations from the group. The long-term future of its First Rail business isn’t entirely clear yet, as management awaits the outcome of the UK government’s review into the structure of the whole rail industry.

Unlocking value

There’s been no further news on the portfolio rationalisation since the plans were announced in May. Meanwhile, at a share price of 129p, the group, as is, trades at 8.9 times forecast current-year earnings.

I’m convinced management is pursuing a strategy that will ultimately unlock value for investors, and I expect to see the shares rate higher through 2020. We should have an update on the rationalisation of the portfolio as early as the company’s half-year results on 14 November.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

SpaceX stock just crashed 50%! Here’s what I’m doing

After all the excitement about that IPO, Harvey Jones says SpaceX stock has lost half its value. Are we suddenly…

Read more »

Space satellite orbiting the earth.
Investing Articles

By mid-2027, analysts expect $3,000 in Tesla stock to be worth…

Tesla stock has taken a backseat to AI chip names recently and this is reflected in its share price. Is…

Read more »

Investing Articles

Is Raspberry Pi stock a future Nvidia?

Are there any similarities between Raspberry Pi and Nvidia? And even if there are, does this make the FTSE 250…

Read more »

piggy bank, searching with binoculars
Investing For Beginners

Down 25% in a week and at 52-week lows, is this UK share now a bargain?

Jon Smith points out a UK share that has been beaten down recently, but could now be undervalued with an…

Read more »

Investing Articles

My favourite FTSE 100 growth stock jumped another 6% today but still trades at a 17% discount!

Harvey Jones is a massive fan of this growth stock and is thrilled to see its shares are climbing again…

Read more »

Elderly, couple hiking and bird watching with adventure outdoor, hike together and fitness for active lifestyle. Nature, trekking and senior man pointing and woman with binocular, freedom and travel.
Investing Articles

Here’s what £5,000 in a best-buy Cash ISA could be worth in July 2027

Harvey Jones says there are some decent Cash ISA rates on the market today but in the longer run stocks…

Read more »

British pound data
Investing Articles

Here’s a £20,000 ISA offering £1,320 a year in passive income

Ben McPoland highlights a five-stock portfolio that could generate a very attractive level of tax-free annual passive income.

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Dividend Shares

By July 2027, £8k paid into a Cash ISA could be worth this much…

Jon Smith explains the benefits of a Cash ISA, but talks through how the elevated reward from dividend shares could…

Read more »